enGenes CEO and co-founder, Dr. Jürgen Mairhofer will be one of the keynote speakers at the conference, presenting the company’s remarkable progress towards the first continuous and sustainable production of proteins in E. coli as part of the ECOnti Project.
Continuous production prototype
ECOnti, which has unveiled a first working prototype of its new platform, depends on enGenes proprietary technologies eXpress® for high-yield Escherichia coli recombinant expression and eXcite®, a cutting-edge technology for continuous manufacturing of biomolecules in E. coli, providing high yield and productivity from a very small footprint.
These capabilities are further leveraged by the Qubicon real-time control platform, novasign and SimVantage process modelling and scale-up tools, Tosoh Bioscience adaptive, multicolumn chromatography for separation and purification, and expertise from Vienna’s University of Natural Resources and Life Sciences (BOKU) in primary recovery, DSP & economic modeling.
Reprogramming E. coli
As part of the conference’s ‘Beyond the Bench’ track, Dr. Mairhofer will deliver one of the Keynote Presentations on Day Two of the conference (September 16; 13:35-14:35 hrs.) with his address ‘Reprogramming E. coli from Genetic Circuits to Continuous Protein and Plasmid DNA Production’. This will detail the ECOnti project and scientific journey behind it, showing how the team has finally been able to tackle the problem of genetic instability, using their combined developed technologies.
He will also explain how the initial ECOnti project for recombinant protein production has opened the way for a second phase, the iCAP (Integrated Continuous and Automated Platform for Plasmid Production) Project that reunites EnGenes with novasign and Qubicon AG in a similar quest to revolutionize manufacturing of pDNA.
Transformational goals
“We feel greatly honored to have been specifically invited to speak at this influential conference,” commented Dr. Mairhofer.
“Apart from being able to show what significant progress we have achieved towards these industry transformational goals, this will also provide a great opportunity to meet some very eminent and expert people in our bioprocessing community, ” he added.
About enGenes Biotech
enGenes Biotech turns biotech innovation into competitive advantage. With more than a decade of proven expertise, they design and deliver next-generation bioprocesses that consistently outperform conventional systems. Powered by their proprietary technology platform, they achieve higher yields, faster development timelines, and seamless scalability for recombinant proteins, peptides, and plasmid DNA in E. coli. The result: significantly reduced production costs and faster time-to-market. From early concept to industrial process, they enable pharmaceutical, synbio, and industrial biotech applications to set new performance benchmarks – at a fraction of the cost.
enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. They deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position on the global marketplace.
The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.
Find out more at: https://www.engenes.cc
About BPN 2025
The BioProcessing Network (BPN) is a not-for-profit association of scientists, engineers, students, and others dedicated to advancing the technologies of the biotech industry, including fermentation, downstream processing, formulation, filling, facility design, and construction to clinical trials and regulatory issues. BPN organises a series of events for the biotechnology and bioprocessing community in Australia and New Zealand, led by its annual technical conference.
The annual conference BPN 2025 is a three-day event opening September 15 at the Pullman (Albert Park) in Melbourne, Victoria, Australia’s second city. Conference themes will include ‘Emerging Platforms and Modalities: Preparing Bioprocessing for the Next Wave’, ‘Beyond the Bench: Rethinking Scale, Design, and Efficiency in Bioprocessing’, ‘Bringing Therapies to Life: Bioprocessing for Regenerative and Personalised Medicine’ and ‘Sustainable by Design: Bioprocessing Solutions for Food, Pharma & Beyond’.
The event is organized by The BioProcessing Network with further details at: https://www.bioprocessingnetwork.org.au
Resources
Click on Contact enGenes to setup one-to-one meeting at the 2025 Bioprocessing Network Conference.
Click on enGenes Biotech’s continuous microbial protein expression and purification to learn more.
Click on ECOnti – Accelerated, Low Ecological Footprint, Manufacturing to download factsheet on project.
COMPANY BROCHURE
enGenes Biotech turns biotech innovation into competitive advantages. With more than a decade of proven expertise, enGenes Biotech designs and delivers next-generation bioprocesses that consistently outperform conventional systems
Contact Information
Address: Muthgasse 11/Stiege 2, 1. Stock, 1190 Vienna, Austria
Telephone No:+43 1 93 46 707-0
Email Address: office(at)engenes.cc
Web Address: http://www.engenes.cc